Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J. Prematta, Tracy Prematta, Timothy Craig

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA. Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks. Methods: The following keywords were searched in PubMed and OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate. Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate-many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years. Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.

Original languageEnglish (US)
Pages (from-to)975-982
Number of pages8
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number5
StatePublished - Dec 1 2008

Fingerprint

Hereditary Angioedemas
English language
Complement C1 Inhibitor Protein
Plasmas
Language
present
Therapeutics
Safety
Standard of Care
PubMed
Placebos
literature
Esterases

All Science Journal Classification (ASJC) codes

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

Prematta, Michael J. ; Prematta, Tracy ; Craig, Timothy. / Treatment of hereditary angioedema with plasma-derived C1 inhibitor. In: Therapeutics and Clinical Risk Management. 2008 ; Vol. 4, No. 5. pp. 975-982.
@article{a28ae1d98aab43f0aead3add02e5c393,
title = "Treatment of hereditary angioedema with plasma-derived C1 inhibitor",
abstract = "Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA. Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks. Methods: The following keywords were searched in PubMed and OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate. Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate-many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years. Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.",
author = "Prematta, {Michael J.} and Tracy Prematta and Timothy Craig",
year = "2008",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "975--982",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "5",

}

Treatment of hereditary angioedema with plasma-derived C1 inhibitor. / Prematta, Michael J.; Prematta, Tracy; Craig, Timothy.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 5, 01.12.2008, p. 975-982.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of hereditary angioedema with plasma-derived C1 inhibitor

AU - Prematta, Michael J.

AU - Prematta, Tracy

AU - Craig, Timothy

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA. Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks. Methods: The following keywords were searched in PubMed and OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate. Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate-many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years. Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.

AB - Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA. Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks. Methods: The following keywords were searched in PubMed and OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate. Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate-many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years. Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.

UR - http://www.scopus.com/inward/record.url?scp=56749136179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749136179&partnerID=8YFLogxK

M3 - Review article

C2 - 19209279

AN - SCOPUS:56749136179

VL - 4

SP - 975

EP - 982

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 5

ER -